Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
12.90
+0.15 (1.18%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Dr. Reddy's Laboratories stock has a consensus rating of "Buy" and an average price target of $13.83. The average 1-year stock price forecast is 7.21% higher than the current stock price, while the lowest is $11.45 (-11.24%) and the highest is $15.52 (+20.31%).
Price Target: $13.83 (+7.21%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Dr. Reddy's Laboratories stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Tausif Shaikh Exane BNP Paribas No rating | Exane BNP Paribas | Buy Upgrades $15 | Buy | Upgrades | $15 | +14.73% | Oct 12, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 1, 2026 |
Unknown Analyst Citi No rating | Citi | Sell Maintains n/a | Sell | Maintains | n/a | n/a | Apr 23, 2026 |
Financial Forecast
Revenue This Year
351.92B
from 335.93B
Increased by 4.76%
Revenue Next Year
393.11B
from 351.92B
Increased by 11.70%
EPS This Year
43.91
from 55.39
Decreased by -20.72%
EPS Next Year
58.81
from 43.91
Increased by 33.93%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.